CAR-T: from bench to bedside

Cover Page

Cite item

Full Text

Abstract

In current immunotherapy, a promising direction is therapy using chimeric antigen receptor T cells (CAR-T). Among malignant hematological diseases, even at advanced stages and resistant/recurrent forms, the use of CAR-T demonstrates high efficiency. The observed clinical success in patients with hematologic malignancies not only determines the ever-increasing list of indications for the use of CAR-T in this group of patients, but also motivates the study of this treatment method in solid oncology and autoimmune diseases. This review examines the history of the emergence and development of CAR-T, the path from the idea of creation to registration to clinical use.

About the authors

M. О. Popova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: marina.popova.spb@gmail.com
ORCID iD: 0000-0001-8536-5495

Marina O. Popova 

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

V. V. Markelov

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0009-0005-5537-6923

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

References

  1. Pavlova A.А., Maschan M.А., Ponomarev V.B. Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors. Onkogematologiya = Oncohematology 2017;12(1):17–32. (In Russ.). doi: 10.17650/1818-8346-2017-12-1-17-32
  2. Razi S., Rezaei N. Introduction on cancer immunotherapy. In: Handbook of cancer and immunology. Ed. N. Rezaei. Springer, Cham, 2023. Available at: https://doi.org/10.1007/978-3-030-80962-1_180-1
  3. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991;(262):3–11.
  4. Coley W.B. The Treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 1910;3 (Surg Sect):1–48.
  5. Pearl R. On the pathological relations between cancer and tuberculosis. Proc Soc Exp Biol Med 1928;26:73–5. doi: 10.3181/00379727-26-4143
  6. Billingham R.E., Brent L., Medawar P.B. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci 1954;143(910):58–80. doi: 10.1098/rspb.1954.00
  7. Mitchison N.A. Passive transfer of transplantation immunity. Nature 1953;171(4345):267–8. doi: 10.1038/171267b0
  8. Gorer P.A. The genetic and antigenic basis of tumour transplantation. J Pathol Bacteriol 1937;44:691–7.
  9. Snell G.D. Some recollections of Peter Gorer and his work on this fiftieth anniversary of his discovery of H-2. Immunogenetics 1986;24(6):339–40. doi: 10.1007/BF00377948
  10. Dausset J. Iso-leuco-anticorps [Iso-leuko-antibodies]. Acta Haematol 1958;20(1–4):156–66. doi: 10.1159/000205478
  11. Edelman G.M. Dissociation of γ-globulin. J Am Chem Soc 1959;81:3155–6.
  12. Porter R.R. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 1959;73(1):119–26. doi: 10.1042/bj0730119
  13. Miller J.F. Immunological function of the thymus. Lancet 1961;2(7205):748–9. doi: 10.1016/s0140-6736(61)90693-6
  14. Cooper M.D., Peterson R.D., Good R.A. Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 1965;205: 143–6. doi: 10.1038/205143a0
  15. Thomas E.D., Lochte H.J., Lu W.C., Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257(11):491–6. doi: 10.1056/NEJM195709122571102
  16. Appelbaum F.R. Hematopoietic-cell transplantation at 50. N Engl J Med 2007;357(15):1472–5. doi: 10.1056/NEJMp078166
  17. The Nobel Prize in Physiology or Medicine 1990. Available at: https://www.nobelprize.org/prizes/medicine/1990/summary/
  18. Mathe G., Amiel J.L., Schwarzenberg L. et al. Haematopoietic chimera in man after allogenic (homologous) bone-marrow transplantation (control of the secondary syndrome. specific tolerance due to the chimerism). Br Med J 1963;2(5373):1633–5. doi: 10.1136/bmj.2.5373.1633
  19. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248(5450):701–2. doi: 10.1038/248701a0
  20. Shimonkevitz R., Kappler J., Marrack P., Grey H. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 1983;158(2):303–16. doi: 10.1084/jem.158.2.303
  21. Townsend A.R., Gotch F.M., Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42(2):457–67. doi: 10.1016/0092-8674(85)90103-5
  22. Reinherz E.L., Meuer S.C., Schlossman S.F. The human T cell receptor: analysis with cytotoxic T cell clones. Immunol Rev 1983;74:83–112. doi: 10.1111/j.1600-065x.1983.tb01085.x
  23. Morgan D.A., Ruscetti F.W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193(4257):1007–8. doi: 10.1126/science.181845
  24. Gillis S., Smith K.A. Long term culture of tumour-specific cytotoxic T cells. Nature 1977;268(5616):154–6. doi: 10.1038/268154a0
  25. Yron I., Wood T.A.J., Spiess P.J., Rosenberg S.A. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980;125(1):238–45.
  26. Lotze M.T., Grimm E.A., Mazumder A. et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981;41(11 Pt 1):4420–5.
  27. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155(6):1823–41. doi: 10.1084/jem.155.6.1823
  28. Mulé J.J., Shu S., Schwarz S.L., Rosenberg S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984;225(4669):1487–9. doi: 10.1126/science.6332379
  29. Mulé J.J., Shu S., Rosenberg S.A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985;135(1):646–52.
  30. Lafreniere R., Rosenberg S.A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985;45(8):3735–41.
  31. Rosenberg S.A., Mulé J.J., Spiess P.J. et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161(5):1169–88. doi: 10.1084/jem.161.5.1169
  32. Rosenberg S.A., Terry W.D. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977;25:323–88. doi: 10.1016/s0065-230x(08)60637-5
  33. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233(4770):1318–21. doi: 10.1126/science.3489291
  34. Fefer A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res 1969;29(12):2177–83.
  35. Glynn J.P., Halpern B.L., Fefer A. An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice. Cancer Res 1969;29(3):515–20.
  36. Rosenberg S.A., Lotze M.T., Muul L.M. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313(23):1485–92. doi: 10.1056/NEJM198512053132327
  37. Rosenberg S.A., Packard B.S., Aebersold P.M. et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319(25):1676–80. doi: 10.1056/NEJM198812223192527
  38. Topalian S.L., Solomon D., Avis F.P. et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6(5):839–53. doi: 10.1200/JCO.1988.6.5.839
  39. Weiden P.L., Flournoy N., Thomas E.D. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts. N Engl J Med 1979;300(19):1068–73. doi: 10.1056/NEJM197905103001902
  40. Kolb H.J., Mittermüller J., Clemm C. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76(12):2462–5.
  41. Kuwana Y., Asakura Y., Utsunomiya N. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987;149(3):960–8. doi: 10.1016/0006-291x(87)90502-x
  42. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibodytype specificity. Proc Natl Acad Sci USA 1989;86(24):10024–8. doi: 10.1073/pnas.86.24.10024
  43. Weissman A.M., Baniyash M., Hou D. et al. Molecular cloning of the zeta chain of the T cell antigen receptor. Science 1988;239(4843):1018–21. doi: 10.1126/science.3278377
  44. Romeo C., Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991;64(5):1037–46. doi: 10.1016/0092-8674(91)90327-u
  45. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991;64(5):891–901. doi: 10.1016/0092-8674(91)90314-o
  46. Letourneur F., Klausner R.D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA 1991;88(20):8905–9. doi: 10.1073/pnas.88.20.8905
  47. Romeo C., Amiot M., Seed B. Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain. Cell 1992;68(5):889–97. doi: 10.1016/0092-8674(92)90032-8
  48. Huston J.S., Levinson D., Mudgett-Hunter M. et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85(16):5879–83. doi: 10.1073/pnas.85.16.5879
  49. Bird R.E., Hardman K.D., Jacobson J.W. et al. Singlechain antigen-binding proteins [published correction appears in Science 1989 Apr 28;244(4903):409]. Science 1988;242(4877):423–6. doi: 10.1126/science.3140379
  50. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90(2):720–4. doi: 10.1073/pnas.90.2.720
  51. Stancovski I., Schindler D.G., Waks T. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993;151(11):6577–82.
  52. Brocker T., Peter A., Traunecker A., Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol 1993;23(7):1435–9. doi: 10.1002/eji.1830230705
  53. Moritz D., Wels W., Mattern J., Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91(10):4318–22. doi: 10.1073/pnas.91.10.4318
  54. Hwu P., Yang J.C., Cowherd R. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55(15):3369–73.
  55. Weijtens M.E., Willemsen R.A., Valerio D. et al. Single chain Ig/ gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996;157(2):836–43.
  56. Gong M.C., Latouche J.B., Krause A. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1(2):123–7. doi: 10.1038/sj.neo.7900018
  57. Haynes N.M., Snook M.B., Trapani J.A. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of singlechain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 2001;166(1):182–7. doi: 10.4049/jimmunol.166.1.182
  58. Dudley M.E., Wunderlich J.R., Robbins P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850–4. doi: 10.1126/science.1076514
  59. Kershaw M.H., Westwood J.A., Parker L.L. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6106–15. doi: 10.1158/1078-0432.CCR-06-1183
  60. Lamers C.H., Sleijfer S., Vulto A.G. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20–2. doi: 10.1200/JCO.2006.05.9964
  61. Park J.R., Digiusto D.L., Slovak M. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825–33. doi: 10.1038/sj.mt.6300104
  62. Till B.G., Jensen M.C., Wang J. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261–71. doi: 10.1182/blood-2007-12-128843
  63. Morgan R.A., Dudley M.E., Wunderlich J.R. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126–9. doi: 10.1126/science.1129003
  64. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233–58. doi: 10.1146/annurev.immunol.14.1.233
  65. Alvarez-Vallina L., Hawkins R.E. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric singlechain antibody variable fragment-CD28 receptors. Eur J Immunol 1996;26(10):2304–9. doi: 10.1002/eji.1830261006
  66. Finney H.M., Lawson A.D., Bebbington C.R., Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161(6):2791–7.
  67. Hombach A., Wieczarkowiecz A., Marquardt T. et al. Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule [published correction appears in J Immunol 2004;173(1):695]. J Immunol 2001;167(11):6123–31. doi: 10.4049/jimmunol.167.11.6123
  68. Maher J., Brentjens R.J., Gunset G. et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20(1):70–5. doi: 10.1038/nbt0102-70
  69. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172(1):104–13. doi: 10.4049/jimmunol.172.1.104
  70. Imai C., Mihara K., Andreansky M. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18(4):676–84. doi: 10.1038/sj.leu.2403302
  71. Milone M.C., Fish J.D., Carpenito C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo [published correction appears in Mol Ther 2015;23(7):1278]. Mol Ther 2009;17(8):1453–64. doi: 10.1038/mt.2009.83
  72. Kochenderfer J.N., Wilson W.H., Janik J.E. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099–102. doi: 10.1182/blood-2010-04-281931
  73. Brentjens R., Yeh R., Bernal Y. et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18(4):666–8. doi: 10.1038/mt.2010.31
  74. Brentjens R.J., Rivière I., Park J.H. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118(18):4817–28. doi: 10.1182/blood-2011-04-348540
  75. Porter D.L., Levine B.L., Kalos M. et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia [published correction appears in N Engl J Med 2016;374(10):998]. N Engl J Med 2011;365(8):725–33. doi: 10.1056/NEJMoa1103849
  76. Melenhorst J.J., Chen G.M., Wang M. et al. Decade-long leukaemia remissions with persistence of CD4+CAR T cells [published correction appears in Nature 2022;612(7941):E22]. Nature 2022;602(7897):503–9. doi: 10.1038/s41586-021-04390-6
  77. Grupp S.A., Kalos M., Barrett D. et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia [published correction appears in N Engl J Med 2016;374(10):998]. N Engl J Med 2013;368(16):1509–18. doi: 10.1056/NEJMoa1215134
  78. Emily is alive today because of cancer research. Available at: https://emilywhiteheadfoundation.org/our-journey/
  79. Maude S.L., Frey N., Shaw P.A. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia [published correction appears in N Engl J Med 2016;374(10):998]. N Engl J Med 2014;371(16):1507–17. doi: 10.1056/NEJMoa1407222
  80. Maude S.L., Laetsch T.W., Buechner J. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378(5):439–48. doi: 10.1056/NEJMoa1709866
  81. O’Leary M.C., Lu X., Huang Y. et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 2019;25(4):1142–6. doi: 10.1158/1078-0432.CCR-18-2035
  82. State register of medicine prices. Registration certificate of the drug Kymriah. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9b10523c-a956-455d-bf97-ef27653f3e44 (In Russ.).
  83. Kochenderfer J.N., Dudley M.E., Kassim S.H. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33(6):540–9. doi: 10.1200/JCO.2014.56.2025
  84. Neelapu S.S., Locke F.L., Bartlett N.L. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531–44. doi: 10.1056/NEJMoa1707447
  85. FDA okays second CAR-T for Kite. Nat Biotechnol 2020;38(9):1012. doi: 10.1038/s41587-020-0676-z
  86. Schuster S.J., Bishop M.R., Tam C.S. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45–56. doi: 10.1056/NEJMoa1804980
  87. Abramson J.S., Palomba M.L., Gordon L.I. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396(10254):839–52. doi: 10.1016/S0140-6736(20)31366-0
  88. Albanyan O., Chavez J., Munoz J. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Ther Adv Hematol 2022;13:20406207221141511. doi: 10.1177/20406207221141511
  89. Locke F.L., Miklos D.B., Jacobson C.A. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640–54. doi: 10.1056/NEJMoa2116133
  90. Kamdar M., Solomon S.R., Arnason J. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial [published correction appears in Lancet 2022;400(10347):160]. Lancet 2022;399(10343): 2294–308. doi: 10.1016/S0140-6736(22)00662-6
  91. Bishop M.R., Dickinson M., Purtill D. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629–39. doi: 10.1056/NEJMoa2116596
  92. Wang M., Munoz J., Goy A. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331–42. doi: 10.1056/NEJMoa1914347
  93. Huang Z., Chavda V.P., Bezbaruah R. et al. CAR T-Cell therapy for the management of mantle cell lymphoma. Mol Cancer 2023;22(1):67. doi: 10.1186/s12943-023-01755-5
  94. Jacobson C.A., Chavez J.C., Sehgal A.R. et al. Axicabtagene ciloleucel in relapsed or refractory indolent nonHodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91–103. doi: 10.1016/S1470-2045(21)00591-X
  95. Fowler N.H., Dickinson M., Dreyling M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28(2):325–32. doi: 10.1038/s41591-021-01622-0
  96. Brentjens R.J., Davila M.L., Riviere I. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38. doi: 10.1126/scitranslmed.3005930
  97. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385(9967):517–28. doi: 10.1016/S0140-6736(14)61403-3
  98. Shah B.D., Ghobadi A., Oluwole O.O. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8
  99. Kalos M., Levine B.L., Porter D.L. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73. doi: 10.1126/scitranslmed.3002842
  100. Gill S., Vides V., Frey N.V. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia [published correction appears in Blood Adv 2023;7(21):6567]. Blood Adv 2022;6(21):5774–85. doi: 10.1182/bloodadvances.2022007317
  101. Siddiqi T., Maloney D.G., Kenderian S.S. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet 2023;402(10402):641–54. doi: 10.1016/S0140-6736(23)01052-8
  102. FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL. Available at: https://www.onclive.com/view/fda-approves-lisocabtagene-maraleucel-for-relapsed-orrefractory-cll-or-sll
  103. Yu B., Jiang T., Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13(1):125. doi: 10.1186/s13045-020-00962-7
  104. Carpenter R.O., Evbuomwan M.O., Pittaluga S. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19(8):2048–60. doi: 10.1158/1078-0432.CCR-12-2422
  105. Raje N., Berdeja J., Lin Y. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380(18):1726–37. doi: 10.1056/NEJMoa1817226
  106. Martin T., Usmani S.Z., Berdeja J.G. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41(6):1265–74. doi: 10.1200/JCO.22.00842
  107. San-Miguel J., Dhakal B., Yong K. et al. Cilta-cell or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335–47. doi: 10.1056/NEJMoa2303379
  108. ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma. Available at: https://www.cancernetwork.com/view/odac-casts-11-to-0-vote-in-favor-of-cilta-cel-in-r-r-multiplemyeloma
  109. Zhang S., Gu C., Huang L. et al. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep 2022;12(1):10488. doi: 10.1038/s41598-022-14523-0
  110. Hill L.C., Rouce R.H., Wu M.J. et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood 2024;143(13):1231–41. doi: 10.1182/blood.2023022204
  111. Zhang Y., Li C., Du M. et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J 2023;13(1):61. doi: 10.1038/s41408-023-00822-w
  112. Xiang J., Devenport J.M., Carter A.J. et al. An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 2023;37(12):2448–56. doi: 10.1038/s41375-023-02039-z
  113. Zhang M., Wei G., Zhou L. et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 2023;10(2):e107–16. doi: 10.1016/S2352-3026(22)00372-6
  114. Brown C.E., Hibbard J.C., Alizadeh D. et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial [published correction appears in Nat Med 2024]. Nat Med 2024. doi: 10.1038/s41591-024-02875-1
  115. Qi C., Gong J., Li J. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 2022;28(6):1189–98. doi: 10.1038/s41591-022-01800-8
  116. Müller F., Taubmann J., Bucci L. et al. CD19 CAR T-cell therapy in autoimmune disease – a case series with follow-up. N Engl J Med 2024;390(8):687–700. doi: 10.1056/NEJMoa2308917
  117. Zheng Z., Li S., Liu M. et al. Fine-tuning through generations: advances in structure and production of CAR-T therapy. Cancers (Basel) 2023;15(13):3476. doi: 10.3390/cancers15133476
  118. https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX%3A32007R1394
  119. Trias E., Juan M., Urbano-Ispizua A., Calvo G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant 2022;57(2):156–9. doi: 10.1038/s41409-021-01463-y
  120. Maschan M., Caimi P.F., Reese-Koc J. et al. Multiple site place-ofcare manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun 2021;12(1):7200. doi: 10.1038/s41467-021-27312-6
  121. Kekre N., Hay K.A., Webb J.R. et al. CLIC-01: manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front Immunol 2022;13:1074740. doi: 10.3389/fimmu.2022.1074740
  122. Sergeev V.S., Emelyanova N.V., Markelov V.V. et al. Production of autologous T-lymphocytes with anti-CD19 chimeric antigen receptor using an automated, completely closed and serum-free technological process. Cell Ther Transplant 2023;12(4):50–7.
  123. A Galapagos company CellPoint. Available at: https://www.glpg.com/about-us/cellpoint/
  124. Kersten M.J., Saevels K., Beguin Y. et al. Seven-day vein-tovein point-of-care manufactured CD19 CAR T cells (GLPG5101) in relapsed/refractory NHL: results from the phase 1 Atalanta-1 trial. Blood 2023;142 (Suppl 1):2113.
  125. Russian newspaper. Federal Law of August 4, 2023 No. 466-FZ “On Amendments to Article 4 of the Federal Law “On the Circulation of Medicines” and the Federal Law “On Biomedical Cell Products”. Available at: https://rg.ru/documents/2023/08/08/fz466-site-dok.html (In Russ.).
  126. Russian newspaper. The Ministry of Health has registered a cancer drug for 39 million rubles. Available at: https://rg.ru/2023/04/19/minzdravzaregistriroval-lekarstvo-ot-raka-za-39-mln-rublej.html (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.